INVASIVE DUCTAL BREAST CARCINOMA

This adverse event was reported 2687 times

These drugs are most commonly taken by patients reporting INVASIVE DUCTAL BREAST CARCINOMA:

# Drug Count
0 LETROZOLE 241
1 LETROZOLE TABLETS 205
2 METHOTREXATE SODIUM 204
3 NATALIZUMAB 189
4 METHOTREXATE 177
5 TRASTUZUMAB 159
6 ERGOCALCIFEROL 154
7 CYCLOPHOSPHAMIDE 147
8 CYCLOPHOSPHAMIDE FOR INJECTION 147
9 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 147
See all common drugs associated with INVASIVE DUCTAL BREAST CARCINOMA

INVASIVE DUCTAL BREAST CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen Receptor Antagonist [EPC] 124 0.0031
1 Aromatase Inhibitor [EPC] 343 0.0031
2 Interleukin-36 Receptor Antagonist [EPC] 1 0.0027
3 HER2/neu Receptor Antagonist [EPC] 160 0.0022
4 Androgen [EPC] 40 0.0015
5 Microtubule Inhibitor [EPC] 239 0.0015
6 Sphingosine 1-phosphate Receptor Modulator [EPC] 16 0.0012
7 Estrogen [EPC] 161 0.0009
8 Leptin Analog [EPC] 1 0.0008
9 Integrin Receptor Antagonist [EPC] 197 0.0007
See all drug classes enriched for association with INVASIVE DUCTAL BREAST CARCINOMA